Research progress of celastrol on the prevention and treatment of metabolic associated fatty liver disease.
- Author:
Yun-Chao LIU
1
;
Ying ZHANG
2
;
Shu-Cun QIN
1
;
Jun-Li XUE
1
Author Information
1. Central Laboratory of the Second Affiliated Hospital, Shandong First Medical University, Taian 271000, China.
2. College of Pharmacy, Shandong First Medical University, Taian 271000, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Non-alcoholic Fatty Liver Disease/metabolism*;
Liver/pathology*;
Pentacyclic Triterpenes/metabolism*;
Obesity
- From:
Acta Physiologica Sinica
2023;75(5):682-690
- CountryChina
- Language:Chinese
-
Abstract:
Metabolic associated fatty liver disease (MAFLD) is a liver disease with hepatocyte steatosis caused by metabolic disorders, which is closely related to obesity, diabetes, metabolic dysfunction, and other factors. Its pathological process changes from simple steatosis, liver inflammation to non-alcoholic steatohepatitis (NASH), and then leads to liver fibrosis, cirrhosis, and liver cancer. At present, no specific therapeutics are available for treatment of MAFLD targeting its etiology. Celastrol is the main active component of the traditional Chinese medicine Celastrus orbiculatus Thunb. In recent years, it has been found that celastrol shows important medicinal value in regulating lipid metabolism, reducing fat and weight, and protecting liver, and then ameliorates MAFLD. This article reviews the related research progress of celastrol in the prevention and treatment of MAFLD, so as to provide a reference for the comprehensive development and utilization of celastrol.
